Nasopharyngeal cancer staging study
Part of Cancer, Ear, nose & throat clinical trials.
This study looks at how well the current cancer staging system works for nasopharyngeal cancer. If you have been diagnosed with this type of cancer between October 2025 and September 2026, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer (a type of cancer in the upper throat behind the nose).
- Your diagnosis was confirmed by a biopsy (tissue sample).
- You were diagnosed between October 1, 2025 and September 30, 2026.
- Your tumor is not a rare type like lymphoma, sarcoma, melanoma, or salivary gland tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
This trial tests a new way of managing advanced nasopharyngeal cancer that has spread to the neck after radiation therapy. It uses regular imaging and exams to guide a less invasive neck surgery, aiming to remove any remaining cancer while preserving healthy tissue.
This trial tests a new treatment plan for nasopharyngeal cancer that avoids platinum-based chemotherapy, which can have harsh side effects. It may help patients with stage II or III disease by using other drugs to control the cancer.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.